Pavel Reiterer

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Luis Paz‐Ares, Helen J. Ross, Mary O’Brien et al. · British Journal of Cancer · 2008 · 167 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Vera Hirsh, Luis Paz‐Ares, Michael Boyer et al. · Journal of Clinical Oncology · 2011 · 139 citations · Full text

Medicine, Oncology, Pharmacology +11

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 104 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer

E.H. Tan, Aleksandra Szczęsna, Maciej Krzakowski et al. · Lung Cancer · 2005 · 57 citations

Medicine, Oncology, Pharmacology +9

Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study

Dragana Jovanović, Martina Šterclová, Nesrin Moğulkoç et al. · Respiratory Research · 2022 · 47 citations · Full text

Medicine, Internal Medicine, Epidemiology +12